We are a biopharma company that partners with top-tier researchers to accelerate new discoveries in the world of medicine, one powerful idea at a time!
It’s always nice to be mentioned with $NVDA… “This treatment is particularly special, as according to the firm, it is the first human data from a genetically modified #T-Cell vaccine.’ #biopharma#discovery $ocea https://t.co/7cvU4LoUxW
Congratulations to our partners at Virion for solid Phase 1 study data, the first ever for a checkpoint modifier containing T cell vaccine of any kind. We are proud of this groundbreaking work towards creating a functional cure for #HBV! $ocea https://t.co/scKxny3kEI
EXCLUSIVE: Ocean Biomedical Announces Publication of Breast Cancer Research On New Tumor Suppression Pathway for Proprietary Antibody $OCEA https://t.co/BmT4ftFeS5 via @Benzinga
Ocean Biomedical’s breast cancer research uncovers new tumor suppression pathway for its proprietary antibody https://t.co/tmM8TBIA8r #cancer#biopharma $ocea
Today, @WHO published the World Malaria Report
📑 which explores the impacts of climate change on #malaria transmission. Robust surveillance 📈 is critical in ensuring malaria programmes can respond to the impact of changing weather.
Read more 📰#COP28 https://t.co/SBT6dVE5Bh
Ocean Biomedical CEO, Elizabeth Ng, CFO Gurinder Kalra, and Executive Chairman, Chirinjeev Kathuria will be presenting today at 12:35pm... Presenting on the Emerging Growth Conference 64 Day 1 on November 1 https://t.co/EVxMJPGELc $ocea
We're in! 🍾 First patients dosed in Hong Kong today in a groundbreaking, international HBV study with our partner Virion Therapeutics, evaluating a new "functional cure" for chronic Hep B infection. #FPI#HBV#biopharma $OCEA https://t.co/WQPnQju7Ph